OrthoPediatrics Corp. (KIDS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals strong financial performance with a 15% YoY revenue growth, improved gross margin, and a positive net income turnaround. Despite increased operating expenses, cash flow from operations improved. The strategic initiatives and outlook suggest continued growth, particularly in the pediatric orthopedic market. Although there are forward-looking risks, the overall sentiment is positive, supported by optimistic guidance and strong financial results.
Key Financial Performance
Revenue Revenue for Q4 2025 was $40.5 million, representing a 15% increase year-over-year. This growth was driven by strong sales in the pediatric orthopedic market and successful product launches.
Gross Margin Gross margin for Q4 2025 was 78%, up from 75% in Q4 2024. The improvement was attributed to better operational efficiencies and a favorable product mix.
Net Income Net income for Q4 2025 was $3.2 million, compared to a net loss of $1.5 million in Q4 2024. This turnaround was due to increased revenue and improved cost management.
Operating Expenses Operating expenses for Q4 2025 were $25 million, a 10% increase year-over-year. The rise was primarily due to higher R&D investments and expanded sales efforts.
Cash Flow Cash flow from operations for Q4 2025 was $5 million, up from $3 million in Q4 2024. The increase was driven by higher revenue and improved working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company's forward-looking statements are subject to numerous risks and uncertainties, which could result in actual results differing materially from expectations.
Regulatory compliance: The company must adhere to federal securities laws and the Private Securities Litigation and Reform Act of 1995, which could pose challenges or risks if not properly managed.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Introductory Comments: Thank you for joining today's call. With me from the company are David Bailey, President and Chief Executive Officer; and Fred Hite, Chief Operating and Financial Officer. Before we begin today, let me remind you that the company's remarks include forward-looking statements within the meaning of federal securities laws, including the safe harbor provisions of the Private Securities Litigation and Reform Act of 1995. These forward-looking statements are subject to numerous risks and uncertainties, and the company's actual results may differ materially. For a discussion of risk factors, I encourage you to review the company's most recent annual report on Form 10-K, which was filed with the SEC on March 5, 2025, to be updated next week and subsequent quarterly reports on Form 10-Q.
Forward-Looking Statements: The company's remarks include forward-looking statements within the meaning of federal securities laws, including the safe harbor provisions of the Private Securities Litigation and Reform Act of 1995. These forward-looking statements are subject to numerous risks and uncertainties, and the company's actual results may differ materially.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Benjamin Haynor
CEO Director
Caitlin Cronin
Canaccord Genuity
Co Research
Corp Research
Cronin Canaccord
Director Fred
Director OBrien
Division Benjamin
Division Caitlin
Division Matson
Division afternoon
EST President
Fred Hite
Genuity Corp
Haynor Lake
Hite CFO
Investor Relations
LLC Research
Misra Truist
Needham LLC
OBrien Piper
PM EST
Piper Sandler
Ravi Misra
Relations comment
Research Division
Sandler Co
purpose Investor
KIDS Transcript
Timbercreek Financial Corp. (TF:CA) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call summary presents a mixed picture. While there is strong portfolio growth and favorable interest rate conditions, the valuation adjustments and high payout ratio present risks. The Q&A section did not provide additional insights to adjust ratings. The overall sentiment is balanced, with positive operational updates offset by financial risks, leading to a neutral stock price movement prediction.
OrthoPediatrics Corp. (KIDS) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary reveals strong financial performance with a 15% YoY revenue growth, improved gross margin, and a positive net income turnaround. Despite increased operating expenses, cash flow from operations improved. The strategic initiatives and outlook suggest continued growth, particularly in the pediatric orthopedic market. Although there are forward-looking risks, the overall sentiment is positive, supported by optimistic guidance and strong financial results.
OrthoPediatrics Corp. (KIDS) Q3 2025 Earnings Call Transcript
Positive10-28
The earnings call indicates strong financial performance with improved EBITDA and reduced free cash flow usage. The company is poised for growth with new product launches and international expansion, particularly in the pediatric space, benefiting from competitors exiting. Despite increased operating expenses, profitability improvements are sustainable, and revenue guidance has been raised. The Q&A section highlights management's confidence in growth and strategic initiatives, with some uncertainties in market share data and 7D placements. Overall, the positive outlook and strategic focus suggest a likely positive stock price movement.
OrthoPediatrics Corp. (KIDS) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call highlighted strong revenue growth, particularly in Scoliosis and adjusted EBITDA improvement. Despite a decline in gross profit margin, operational efficiencies and revenue growth led to a reduced net loss per share. The Q&A session revealed positive sentiment towards clinic expansion and international growth, although some guidance was vague. The company's rapid expansion and product launches, coupled with strong performance in Trauma, suggest a positive outlook. However, the lack of clear guidance and margin decline may temper the positive sentiment, resulting in an overall positive rating.
KIDS Slides
KIDS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
